Skip to main content

Table 2 Unadjusted hazard ratios for recurrence in relation to stromal ER and PR expression, allover and stratified by KRAS mutation status and sex, respectively

From: Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma

 AllKRAS wild-typeKRAS mutated 
n (events)HR (95% CI)n (events)HR (95% CI)n (events)HR (95% CI)Pinteraction
ER status
 All
  ER-118 (84)1.0040 (23)1.0034 (29)1.000.078
  ER+48 (36)0.90 (0.61–1.33)13 (10)1.49 (0.71–3.15)12 (8)0.54 (0.24–1.19)0.056a
  p 0.587 0.294 0.127 
 Women
  ER-49 (32)1.0017 (9)1.0014 (10)1.000.544
  ER+35 (24)0.97 (0.57–1.65)8 (5)1.33 (0.44–4.00)8 (5)0.84 (0.28–2.53)0.425a
  p 0.905 0.615 0.760 
 Men
  ER-69 (52)1.0023 (14)1.0020 (19)1.000.025
  ER+13 (12)1.02 (0.54–1.92)5 (5)2.30 (0.78–6.78)4 (3)0.31 (0.08–1.11)0.015a
  p 0.951 0.131 0.072 
PR status
 All
  PR-111 (77)1.0038 (21)1.0029 (26)1.000.005
  PR+49 (40)1.25 (0.85–1.83)12 (10)2.07 (0.97–4.42)17 (12)0.50 (0.25–0.99)0.008a
  p 0.252 0.061 0.048b 
 Women
  PR-52 (33)1.0018 (9)1.0012 (10)1.000.005
  PR+28 (22)1.35 (0.79–2.33)6 (5)2.71 (0.89–8.26)9 (5)0.32 (0.11–0.97)0.011a
  p 0.276 0.080 0.043b 
 Men
  PR-59 (44)1.0020 (12)1.0017 (16)1.000.337
  PR+21 (18)1.20 (0.69–2.08)6 (5)1.64 (0.58–4.70)8 (7)0.84 (0.34–2.09)0.249a
  p 0.510 0.353 0.715 
  1. aInteraction analysis including adjustment for morphological type (I-type/PB-type)
  2. bHazard ratio adjusted for morphological type 0.46 (0.23–0.93) in the entire cohort, and 0.32 (0.11–0.96) in women